Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-09-30 am EDT
3767.00 JPY   -0.24%
09/30Takeda - Strengthening Healthcare Systems to Meet Patients Need for Plasma-Derived Therapies
AQ
09/29Strengthening Healthcare Systems to Meet Patients' Need for Plasma-Derived Therapies
BU
09/29Takeda Pharmaceutical Company Limited and United Nations Institute for Training and Research Strengthening Healthcare Systems to Meet Patients' Need for Plasma-Derived Therapies
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : Quarterly Securities Report for the 1st Quarter

08/04/2022 | 03:07am EDT

Table of Contents

Quarterly Securities Report

(The first quarter of 146th Business Term)

for The Three-month Period Ended June 30, 2022

TAKEDA PHARMACEUTICAL COMPANY LIMITED

AND ITS SUBSIDIARIES

Table of Contents

Index

Page

[Cover]

1

A. Company Information

I. Overview of Takeda

2

1.

Key Consolidated Financial Data

2

2.

Business Overview

2

II. Operating and Financial Review

3

1.

Risk Factors

3

2.

Analysis on Business Performance, Financial Position and Cash Flows

3

3.

Material Contracts

15

III. Information on the Company

16

1.

Information on the Company's Shares

16

2.

Members of the Board of Directors

18

IV. Financial Information

19

1.

Condensed Interim Consolidated Financial Statements

20

2.

Others

37

B. Information on Guarantors of the Company

38

Table of Contents

[Cover]

[Document Filed]

Quarterly Securities Report

[Applicable Law]

Article 24-4-7, paragraph 1 of the Financial Instruments and Exchange Act of Japan

[Filed with]

Director, Kanto Local Finance Bureau

[Filing Date]

August 4, 2022

[Fiscal period]

The first quarter of 146th Business Term

(from April 1, 2022 to June 30, 2022)

[Company Name]

Takeda Pharmaceutical Company Limited

[Title and Name of Representative]

Christophe Weber, Representative Director, President & Chief Executive Officer

[Address of Head Office]

1-1, Doshomachi 4-chome,Chuo-ku, Osaka

(The above address is the registered head office location and the ordinary business

operations are conducted at the "Nearest Place of Contact")

[Telephone Number]

Not applicable

[Name of Contact Person]

Not applicable

[Nearest Place of Contact]

1-1,Nihonbashi-Honcho2-chome,Chuo-ku, Tokyo

(Global Headquarters)

[Telephone Number]

+81-3-3278-2111 (Main telephone number)

[Name of Contact Person]

Norimasa Takeda, Chief Accounting Officer & Corporate Controller, Global Finance

[Place for public inspection]

Takeda Pharmaceutical Company Limited (Global Headquarters)

(1-1, Nihonbashi Honcho 2-chome,Chuo-ku, Tokyo)

Tokyo Stock Exchange, Inc.

(2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo)

Nagoya Stock Exchange, Inc.

(8-20, Sakae 3-chome,Naka-ku, Nagoya)

Fukuoka Stock Exchange

(14-2, Tenjin 2-chome,Chuo-ku, Fukuoka)

Sapporo Stock Exchange

(14-1, Minamiichijonishi 5-chome,Chuo-ku, Sapporo)

- 1 -

Table of Contents

A. Company Information

I. Overview of Takeda

1. Key Consolidated Financial Data

JPY (millions), unless otherwise indicated

Three-month period

Three-month period

For the year ended

ended June 30,

ended June 30,

March 31,

Term

2021

2022

2022

Revenue

949,603

972,465

3,569,006

Profit before tax

222,978

155,473

302,571

Net profit for the period

137,726

105,021

230,166

Net profit attributable to owners of the Company

137,684

105,014

230,059

Total comprehensive income for the period

197,005

784,617

824,427

Total equity

5,238,643

6,317,383

5,683,523

Total assets

12,657,234

14,065,426

13,178,018

Basic earnings per share (JPY)

87.96

67.94

147.14

Diluted earnings per share (JPY)

87.45

67.56

145.87

Ratio of equity attributable to owners of the Company to

total assets (%)

41.4

44.9

43.1

Net cash from (used in) operating activities

166,858

84,241

1,123,105

Net cash from (used in) investing activities

(70,445)

(94,714)

(198,125)

Net cash from (used in) financing activities

(411,038)

(215,717)

(1,070,265)

Cash and cash equivalents at the end of the period

654,920

645,991

849,695

(Note 1) All amounts shown are rounded to the nearest million JPY.

(Note 2) The key consolidated financial data for the three-month period ended June 30, 2021 and 2022 are based on the condensed interim consolidated financial statements prepared in accordance with IAS 34.

2. Business Overview

There has been no significant change in our business and our group companies for the three-month period ended June 30, 2022. As of June 30, 2022, Takeda consisted of 223 entities comprised of 206 consolidated subsidiaries (including partnerships), 16 associates accounted for using the equity method, and Takeda Pharmaceutical Company Limited. There has been no significant change in our group companies for the three-month period ended June 30, 2022.

- 2 -

Table of Contents

II. Operating and Financial Review

  1. Risk Factors
    For the three-month period ended June 30, 2022, there were no unusual changes in our business performance, financial position, and cash flows, as well as no significant changes in the risk factors compared to what we reported in our Annual Securities Report for the year ended March 31, 2022 which was filed in Japan.
  2. Analysis on Business Performance, Financial Position and Cash Flows

(1) Consolidated Financial Results (April 1 to June 30, 2022)

Billion JPY or percentage

FY2021 Q1

FY2022 Q1

Change versus the same period of the previous fiscal year

Actual % Change

CER % Change*1

Revenue

949.6

972.5

22.9

2.4 %

(6.8)%

Cost of sales

(241.3)

(292.9)

(51.6)

21.4

%

11.3 %

Selling, general and administrative expenses

(219.8)

(231.5)

(11.6)

5.3

%

(4.4)%

Research and development expenses

(122.5)

(143.6)

(21.1)

17.2 %

4.4 %

Amortization and impairment losses on intangible

(102.8)

(131.3)

(28.5)

27.7

%

12.5 %

assets associated with products

Other operating income

11.1

5.5

(5.6)

(50.7)%

(52.5)%

Other operating expenses

(25.8)

(28.2)

(2.4)

9.4

%

(6.2)%

Operating profit

248.6

150.5

(98.0)

(39.4)%

(42.2)%

Finance income and (expenses), net

(25.2)

5.5

30.7

Share of loss of investments accounted for using

(0.4)

(0.5)

(0.1)

39.3

%

(2.0)%

the equity method

Profit before tax

223.0

155.5

(67.5)

(30.3)%

(33.7)%

Income tax expenses

(85.3)

(50.5)

34.8

(40.8)%

(41.7)%

Net profit for the period

137.7

105.0

(32.7)

(23.7)%

(28.7)%

*1 Please refer to Core Results (April 1 to June 30, 2022), Definition of Core financial measures and Constant Exchange Rate change, for the definition.

Revenue. Revenue for the three-month period ended June 30, 2022 was 972.5 billion JPY, an increase of 22.9 billion JPY, or 2.4% (CER % change: -6.8%), compared to the same period of the previous fiscal year. The increase is primarily attributable to growth from business momentum and favorable foreign exchange rates, offsetting the decrease of revenue in the current period due to sale of a portfolio of diabetes products in Japan to Teijin Pharma Limited for 133.0 billion JPY, which was recorded as revenue in the same period of the previous fiscal year.

Revenue of our core therapeutic areas (i.e. Gastroenterology ("GI"), Rare Diseases, Plasma-Derived Therapies ("PDT") Immunology, Oncology, and Neuroscience) increased by 145.8 billion JPY, or 20.6%, compared to the same period of the previous fiscal year, to 853.8 billion JPY. Each of our core therapeutic areas, except Oncology, contributed to positive revenue growth due to growth from business momentum and favorable foreign exchange rates. Generic erosion and intensified competition impacted certain Oncology products in the current period.

Revenue outside of our core therapeutic areas significantly decreased by 123.0 billion JPY, or 50.9%, compared to the same period of the previous fiscal year to 118.7 billion JPY, largely due to the aforementioned non-recurring 133.0 billion JPY selling price of the diabetes portfolio in Japan recorded as revenue in the same period of the previous fiscal year.

- 3 -

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Takeda Pharmaceutical Co. Ltd. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 07:06:05 UTC.


© Publicnow 2022
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09/30Takeda - Strengthening Healthcare Systems to Meet Patients Need for Plasma-Derived Ther..
AQ
09/29Strengthening Healthcare Systems to Meet Patients' Need for Plasma-Derived Therapies
BU
09/29Takeda Pharmaceutical Company Limited and United Nations Institute for Training and Res..
CI
09/29TAKEDA PHARMACEUTICAL COMPANY LIMITED : Ex-dividend..
FA
09/27Takeda Pharmaceutical Company Limited Issues Notice of Redemption to the Holders of 4.4..
CI
09/20Puma Biotech in Exclusive License Deal With Takeda
DJ
09/20Takeda Pharmaceutical Says Health Canada Authorized Treatment for Post-Transplant Cytom..
MT
09/20Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatm..
AQ
09/19Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewa..
BU
09/16Takeda Pharmaceutical Says It Received Positive Opinion for Post-Transplant Cytomegalov..
MT
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2023 3 781 B 26 131 M 26 131 M
Net income 2023 311 B 2 153 M 2 153 M
Net Debt 2023 2 916 B 20 154 M 20 154 M
P/E ratio 2023 18,8x
Yield 2023 4,78%
Capitalization 5 845 B 40 398 M 40 398 M
EV / Sales 2023 2,32x
EV / Sales 2024 2,24x
Nbr of Employees 47 347
Free-Float 96,4%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 767,00 JPY
Average target price 4 588,00 JPY
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Masami Iijima Chairman
Andrew S. Plump Director, President-Research & Development
Michael E. Mendelsohn Chief Medical & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED20.08%40 398
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296